{"prompt": "['Novartis', 'Confidential', 'Page 11', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Study treatment', 'When the subject permanently stops taking study treatment prior to the', 'discontinuation', 'defined study treatment completion date', 'Subject', 'An individual who has consented to participate in this study. The term', 'Subject may be used to describe either a healthy volunteer or a patient.', 'Subject number', 'A unique number assigned to each subject upon signing the informed', 'consent. This number is the definitive, unique identifier for the subject and', 'should be used to identify the subject throughout the study for all data', 'collected, sample labels, etc.', 'Variable', 'A measured value or assessed response that is determined in specific', 'assessments and used in data analysis to evaluate the drug being tested in', 'the study', 'Withdrawal of', 'Withdrawal of consent from the study is defined as when a subject does not', 'consent (WoC)', 'want to participate in the study any longer, and does not want any further', 'visits or assessments, and does not want any further study related contact,', 'and does not allow analysis of already obtained biologic material']['Novartis', 'Confidential', 'Page 12', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Amendment 3', 'Amendment rationale', 'The protocol is being amended to provide clarification on the process for assessment of nasal', 'endoscopy at baseline and management of protocol deviations in relation to the statistical', 'analysis sets. These changes include:', 'Changes in Section 8.3.1 to remove the constraint around the performance of the nasal', 'endoscopy at the end of run-in/baseline visit along with confirming that patient', 'eligibility will be based on the central reading score', 'Change to the text in Section 12.1 to highlight that the Full Analysis Set will only', 'comprise of patients with a baseline NPS > 4, confirmed by central reading', 'Addition of text in Section 12.4 to clarify that the central reading score is what will be', 'used for the primary endpoint analysis', 'Addition of text in Appendix 7 to clarify that the central reading score is the final', 'determination of eligibility at both screening and end of run-in/baseline.', 'IRB Section', 'The changes described in this protocol have been classed as non-substantial and will not require', 'additional IRB/HA approval, unless required by local regulations.']['Novartis', 'Confidential', 'Page 13', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Amendment 2', 'Amendment rationale', 'The protocol is being amended to align the safety requirements with other studies in the', 'QAW039 program. These changes include:', 'Addition of exclusion criteria to align with other QAW039 studies in Section 5.2', 'Update to contraception exclusion criteria to reference that any local deviations from the', 'contraception requirements will apply and will be described within the patient informed', 'consent form. Updates also included to align exclusion criteria with the prohibited', 'medications in Table 6-2', 'Update to asthma inclusion criteria throughout the protocol to remove reference to Global', 'Initiative for Asthma (GINA) Step 3 in order to remove any contradiction and discrepancy', 'with other QAW039 trials given this is a new population.', 'Inclusion of Table 6-1 - Medications allowed under certain conditions - in Section 6.2.1', 'Inclusion of renal safety monitoring in Section 10.2.2 and additional details as an', 'appendix in Section 16.3', 'Addition of urine pregnancy testing at each treatment visit', 'Addition of liver event and renal event monitoring to each visit in Table 8-1', 'Inclusion of clinical chemistry reflex testing in the event of elevated creatine kinase (CK)', 'results in Table 8-4', 'Addition of hemoglobin Alc (HbA1c) testing at Screening and end of treatment (EOT)', 'with updates to Table 8-1 and Table 8-4', 'Changes to the protocol', 'The described changes in the aforementioned amendment rationale are implemented throughout', 'the protocol in the sections noted.', 'The opportunity was also taken to make the following changes in the protocol:', 'Changes made in Table 8-1 to clarify which assessments are performed prior to the start', 'of treatment at the Week 1 visit. Other minor clarification changes also included in this', 'table.', 'Addition of patient withdrawal criteria in Section 9.1.1 relating to the need for nasal', 'surgery during the trial, use of corticosteroids during the trial and also for persistent', 'muscle pain, with or without elevated CK levels.', 'Clarification of Nasal Endoscopy readings / assessments being performed centrally and', 'locally', 'Addition of sensitivity analyses in Section 12.4.4', 'Typographical changes throughout for spelling/consistency.', 'IRB Section', 'A copy of this amended protocol will be sent to the Institutional Review Board', '(IRB)/Independent Ethics Committee (IEC) and Health Authorities.']\n\n###\n\n", "completion": "END"}